Clinical Guidelines
FDA & Government News

FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma

Nivolumab (Opdivo) with doxorubicin, vinblastine, and dacarbazine (AVD) was approved today for adult and pediatric patients aged 12 years and older with previously untreated stage III or IV classical ...

Share

On March 20, the FDA approved nivolumab (Opdivo) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for adults and adolescents (12+) with untreated stage III or IV classical Hodgkin lymphoma. Nivolumab, which previously received accelerated approval for relapsed cases, demonstrated improved progression-free survival compared to brentuximab vedotin plus AVD in a trial involving 994 patients. Serious adverse reactions occurred in 39% of those receiving nivolumab. Recommended dosing involves administration every 28 days for up to six cycles.

Original Source(s)

FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma

  • by The ASCO Post Staff

  • March 20, 2026

Related Content

MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma

For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv pl...

Coalition urges Congress to boost CDC tobacco prevention funding

The ADA joined a coalition urging Congress to provide $310 million for tobacco prevention and cessation programs at the CDC.

Hoth Applies AI in Development of Candidate for KIT-Driven Cancers

Preclinical results and AI integration support progress toward regulatory submission